MediWound Ltd. (MDWD) Income Statement
MDWD 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsMDWD revenue and net income
Where MDWD's revenue goes
2025Each bar shows an amount and its share of revenue. MDWD kept −140.8% of revenue as net income.
MDWD profit margins
MDWD growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −16.1% | −13.8% | −4.9% | +39.7% |
| Gross profit | +23.5% | −37.2% | −15.5% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
MDWD quarterly EPS vs estimates
MediWound beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 19, 2026 (estimate $-0.66).
MDWD income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $17.0M | $20.2M | $18.7M | $26.5M | $23.8M | $21.8M | $31.8M | $3.4M | $2.5M | $1.6M |
| Cost of revenue | $13.7M | $17.6M | $15.1M | $13.3M | $15.0M | $14.2M | $11.8M | $2.1M | $1.6M | $2.2M |
| Gross profit | $3.3M | $2.6M | $3.6M | $13.2M | $8.8M | $7.5M | $19.9M | $1.3M | $918,000 | −$600,000 |
| Research & development | $14.3M | $8.9M | $7.5M | $10.2M | $10.3M | $7.7M | $5.0M | $4.1M | $5.5M | $7.1M |
| Sales, general & admin | $13.9M | $12.9M | $11.4M | $10.4M | $9.5M | $8.5M | $9.1M | $3.8M | $9.1M | $12.4M |
| Total operating expenses | $28.5M | $22.0M | $19.1M | $20.8M | $20.0M | $16.4M | $15.4M | $5.3M | $14.6M | $19.6M |
| Operating income | −$25.3M | −$19.4M | −$15.5M | −$7.7M | −$11.2M | −$8.8M | $4.5M | −$4.0M | −$13.7M | −$20.2M |
| Interest income | $1.9M | $2.0M | $2.3M | $270,000 | $11,000 | $297,000 | $434,000 | $412,000 | $349,000 | $414,000 |
| Interest expense | $662,999 | $561,000 | $335,000 | $162,000 | $167,000 | $200,000 | $207,000 | $892,000 | $827,000 | $847,000 |
| Income before taxes | −$23.7M | −$30.2M | −$6.5M | −$19.5M | −$13.5M | −$9.3M | $2.1M | −$5.7M | −$14.5M | −$18.9M |
| Income taxes | $169,000 | $61,000 | $185,000 | $78,000 | $27,000 | $325,000 | −$1.7M | −$9.7M | $8.5M | −$1.3M |
| Net income | −$23.9M | −$30.2M | −$6.7M | −$19.6M | −$13.6M | −$9.2M | $5.0M | −$1.1M | −$22.1M | −$18.9M |
| EBITDA | −$21.5M | −$27.9M | −$4.8M | −$18.2M | −$11.4M | −$7.4M | $4.1M | −$4.2M | −$13.1M | −$17.4M |
| EPS (diluted) | −$2.10 | −$3.07 | −$0.77 | −$3.84 | −$3.43 | −$2.31 | $0.56 | −$3.36 | −$4.55 | −$6.02 |
| Gross margin | 19.2% | 13.0% | 19.1% | 49.7% | 36.9% | 34.7% | 62.7% | 38.6% | 36.8% | −38.5% |
| Operating margin | −149.1% | −95.8% | −83.0% | −28.9% | −47.2% | −40.6% | 14.1% | −116.4% | −548.4% | −1,293.6% |
| Net margin | −140.8% | −149.5% | −35.9% | −74.0% | −57.0% | −42.3% | 15.6% | −31.1% | −887.4% | −1,212.1% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.1M | $1.5M | $1.9M | $5.4M | $5.7M | $4.0M | $5.8M | $4.4M | $5.1M | $5.0M | $5.3M | $4.8M |
| Cost of revenue | $2.8M | $1.2M | $1.6M | $4.5M | $4.4M | $3.2M | $4.9M | $3.7M | $4.6M | $4.4M | $4.6M | $3.9M |
| Gross profit | $337,000 | $323,000 | $278,000 | $896,000 | $1.3M | $738,000 | $903,000 | $677,000 | $447,000 | $607,000 | $719,000 | $896,000 |
| Research & development | $5.9M | $5.2M | $4.5M | $3.5M | $3.5M | $2.9M | $3.0M | $2.5M | $1.9M | $1.5M | $1.8M | $1.5M |
| Sales, general & admin | $3.9M | $2.3M | $3.8M | $4.0M | $3.6M | $3.1M | $4.0M | $3.2M | $3.0M | $2.9M | $6.8M | $1.4M |
| Total operating expenses | $9.8M | $8.3M | $8.1M | $7.4M | $7.1M | $6.0M | $7.0M | $5.8M | $4.9M | $4.3M | $4.6M | $3.9M |
| Operating income | −$9.5M | −$8.0M | −$7.8M | −$6.5M | −$5.7M | −$5.2M | −$6.1M | −$5.1M | −$4.5M | −$3.7M | −$3.9M | −$3.0M |
| Interest expense | $1.1M | — | — | — | $8.0M | — | — | $5.2M | $2.4M | $6.0M | $6.0M | — |
| Income before taxes | −$7.4M | −$3.0M | −$7.1M | −$2.6M | −$13.3M | −$721,000 | −$3.9M | −$10.3M | −$6.3M | −$9.7M | −$1.6M | −$2.1M |
| Income taxes | $33,000 | −$17,000 | $73,000 | $53,000 | $38,000 | $5,000 | $18,000 | $21,000 | −$2,000 | $24,000 | $120,000 | $48,000 |
| Net income | −$7.4M | −$3.0M | −$7.2M | −$2.7M | −$13.3M | −$726,000 | −$3.9M | −$10.3M | −$6.3M | −$9.7M | −$1.7M | −$2.2M |
| EBITDA | −$9.1M | −$2.6M | −$5.2M | −$2.2M | −$4.9M | −$363,000 | −$15.7M | −$4.7M | −$3.5M | −$3.4M | $5.6M | −$1.8M |
| EPS (diluted) | −$0.77 | −$0.23 | −$0.56 | −$0.24 | −$1.23 | −$0.07 | −$0.36 | −$0.98 | −$0.68 | −$1.05 | −$0.19 | −$0.24 |
| Gross margin | 10.9% | 21.9% | 14.9% | 16.5% | 23.5% | 18.7% | 15.5% | 15.5% | 8.8% | 12.2% | 13.5% | 18.8% |
| Operating margin | −305.9% | −541.0% | −418.5% | −120.2% | −100.1% | −132.1% | −104.2% | −116.7% | −88.6% | −75.2% | −72.9% | −63.3% |
| Net margin | −239.1% | −200.1% | −384.7% | −48.8% | −233.3% | −18.4% | −66.9% | −236.1% | −124.5% | −196.0% | −32.7% | −46.0% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in MDWD's financial statements (latest annual report filed March 5, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
MDWD financial results
In fiscal year 2025 (ended December 31, 2025), MediWound reported revenue of $17.0 million, down 16.1% from the year before. It had a net loss of $23.9 million, a net profit margin of −140.8%. Diluted earnings per share came to −$2.10. Over five years revenue grew at an average rate of −4.9% a year.
See the MDWD stock overview for the latest quote and news, or the MDWD chart for price history and technical indicators.
MDWD income statement FAQ
What is MediWound's annual revenue?
MediWound reported total revenue of $17.0 million for fiscal year 2025, which ended on December 31, 2025. That was down 16.1% from $20.2 million the previous year.
Is MediWound profitable?
No. MediWound reported a net loss of $23.9 million in fiscal 2025, a net profit margin of −140.8%; its operating margin was −149.1%.
What is MediWound's gross margin?
MediWound's gross margin was 19.2% in fiscal 2025: for every $100 of revenue, MediWound kept $19 after the direct cost of its products and services.
How much does MediWound spend on research and development?
MediWound spent $14.3 million on research and development in fiscal 2025, 84.4% of revenue.
How fast is MediWound growing?
Revenue grew −4.9% a year on average over the last five fiscal years, from $21.8 million to $17.0 million.
What are MediWound's earnings per share?
MediWound earned $-2.10 per diluted share in fiscal 2025, compared with $-3.07 a year earlier.
When will MediWound report its next earnings?
MediWound is expected to report results for the quarter ending September 30, 2026 on November 19, 2026 before the market opens.
When does MediWound's fiscal year end?
MediWound's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 5, 2026.